MilliporeSigma Teams Up with Opentrons Labworks for Innovation
In a significant move to revolutionize laboratory automation, MilliporeSigma, the life science arm of Merck KGaA, Darmstadt, Germany, has joined forces with Opentrons Labworks, Inc. This partnership heralds a new era for laboratories, focusing on making lab robotics more accessible and efficient. The alliance is set to automate assay kits utilizing the custom Opentrons Flex workstation over a multi-year agreement.
A Collaborative Effort for Increased Efficiency
Through this collaboration, scientists and engineers from both organizations will work together to develop and validate new workflows. This initiative will leverage a comprehensive range of automation-enabled assays offered by MilliporeSigma. The end goal is to enhance consistency and throughput while significantly minimizing manual processing and repetitive tasks. The user-friendly robotic systems promised by this partnership aim to empower scientists, allowing them to channel their focus toward more complex and rewarding tasks.
Enhancing Productivity While Reducing Manual Work
Jean-Charles Wirth, Head of Science & Lab Solutions for MilliporeSigma, highlights a crucial sentiment among their customers: the need for tools that boost reproducibility and productivity. The partnership with Opentrons is a testament to this vision. By automating and digitizing laboratory processes, scientists can now enhance efficiency during research phases, thereby increasing success rates when developing potential therapeutics.
Innovative Solutions for Diverse Applications
The introduction of the workstations and assay kits is anticipated to commence mid-2025, with applications spanning various workflows. This includes protein sample preparation, molecular and cell workflows, and other biochemical and chemistry-related processes. This represents a significant step forward in the way laboratories will operate, as it integrates advanced technologies into everyday research activities.
Commitment to Accessible Lab Automation
Jonathan Brennan-Badal, CEO of Opentrons, reflects on the mutual objective of broadening access to lab automation tools. He emphasizes that their partnership with MilliporeSigma is propelled by a shared vision to provide cutting-edge solutions. With MilliporeSigma's well-established reputation in pharmaceutical development and manufacturing, combined with Opentrons’ automation prowess, the collaboration promises a transformative experience for laboratories across the globe.
Streamlining Research Through Collaboration
The powerful combination of Opentrons' automation expertise with the robust research and development capabilities of MilliporeSigma aims to yield reliable products that simplify the entire research spectrum, from sample preparation to analysis. Areas such as immunodetection, protein research, enzyme technology, and genome editing will benefit immensely from this collaboration, resulting in more efficient workflows.
Advancements in Biology Innovations
This initiative aligns well with MilliporeSigma’s ongoing commitment to drive innovation within biology. Their existing products, such as the Millicell DCI Digital Cell Imager, have already contributed to more effective cell culture analysis, paving the way for advanced biological solutions. Furthermore, MilliporeSigma’s recent acquisition of HUB Organoids Holding B.V. signifies their dedication to enhancing life science solutions continually.
About MilliporeSigma
MilliporeSigma operates as the life science division of Merck KGaA, Darmstadt, Germany, employing over 28,000 individuals and encompassing more than 55 manufacturing and testing facilities worldwide. Their extensive portfolio features more than 300,000 products targeting scientific research, biomanufacturing, and testing services. Known for impactful contributions across healthcare, life sciences, and electronics, Merck's longstanding history underscores its commitment to driving innovation and advancing technology to better lives.
About Opentrons
Opentrons Labworks, Inc. stands as a leading disruptive entity in life science, defining the market for entry-level lab automation. With its integrated platform and over $200 million in funding, Opentrons has achieved unicorn status fueled by its innovative solutions. The latest product, the Opentrons Flex, embodies their commitment to making lab automation accessible while integrating compatibility with generative AI tools. Used in prominent labs, Opentrons continues to reshape the landscape of laboratory operations globally.
Frequently Asked Questions
What is the main goal of the MilliporeSigma and Opentrons partnership?
The partnership aims to automate various laboratory processes to improve efficiency, consistency, and throughput in research environments.
When can customers expect to order the new workstations and assay kits?
Orders are expected to be available starting in mid-2025.
What types of workflows will benefit from this collaboration?
The collaboration will enhance workflows involving protein sample preparation, molecular, cell, biochemical, and chemistry processes.
How does this partnership aim to improve lab productivity?
By reducing manual tasks and increasing automation, the partnership allows scientists to focus on more complex aspects of their research.
What does Opentrons bring to the partnership with MilliporeSigma?
Opentrons offers expertise in lab automation and a robust platform that enhances accessibility and efficiency in laboratory procedures.
